Literature DB >> 22732770

[Potential interactions of rheumatologic medications in the elderly].

U Lange1, U Müller-Ladner.   

Abstract

Improving the safety of prescriptions for elderly patients is of substantial interest for physicians of all specialities as well as for general health policy and health services. Owing to the increase in drug prescriptions with age and various drug-drug interactions, the number of adverse drug event-related hospital admissions needs to be minimized as far as possible. Therefore, the present overview focuses on the most important potential drug-drug interactions with a specific focus on antirheumatic medications prescribed for elderly patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22732770     DOI: 10.1007/s00132-012-1930-y

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  24 in total

Review 1.  ABC of the upper gastrointestinal tract: Indigestion and non-steroidal anti-inflammatory drugs.

Authors:  J M Seager; C J Hawkey
Journal:  BMJ       Date:  2001-11-24

2.  Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly.

Authors:  Kathrine F Vandraas; Olav Spigset; Milada Mahic; Lars Slørdal
Journal:  Eur J Clin Pharmacol       Date:  2010-04-20       Impact factor: 2.953

3.  Prevalence of potentially hazardous drug interactions amongst Australian veterans.

Authors:  Elizabeth E Roughead; Lisa M Kalisch; John D Barratt; Andrew L Gilbert
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

4.  Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin.

Authors:  H T Sørensen; L Mellemkjaer; W J Blot; G L Nielsen; F H Steffensen; J K McLaughlin; J H Olsen
Journal:  Am J Gastroenterol       Date:  2000-09       Impact factor: 10.864

5.  Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy.

Authors:  Jana L Antohe; Androniki Bili; Jennifer A Sartorius; H Lester Kirchner; Stephanie J Morris; Sorina Dancea; Mary Chester M Wasko
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-02       Impact factor: 4.794

6.  Potentially inappropriate medications in the elderly: the PRISCUS list.

Authors:  Stefanie Holt; Sven Schmiedl; Petra A Thürmann
Journal:  Dtsch Arztebl Int       Date:  2010-08-09       Impact factor: 5.594

7.  Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.

Authors:  E E A Arts; T L Jansen; A Den Broeder; H E Vonkeman; E Dutmer; M A F J Van de Laar; P L C M Van Riel; J Fransen
Journal:  Ann Rheum Dis       Date:  2010-10-18       Impact factor: 19.103

Review 8.  An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.

Authors:  Eric N van Roon; Patricia M L A van den Bemt; Tim L Th A Jansen; Nella M Houtman; Mart A F J van de Laar; Jacobus R B J Brouwers
Journal:  Clin Ther       Date:  2009-08       Impact factor: 3.393

Review 9.  Antiplatelet drug interactions.

Authors:  I S Mackenzie; M W H Coughtrie; T M MacDonald; L Wei
Journal:  J Intern Med       Date:  2010-11-14       Impact factor: 8.989

10.  Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).

Authors:  Gerd R Burmester; E Feist; H Kellner; J Braun; C Iking-Konert; A Rubbert-Roth
Journal:  Ann Rheum Dis       Date:  2010-12-27       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.